Figure 1.
Patient enrollment and participation flow chart.
* Patients were enrolled on the Intermittent dosing schedule first, and then enrolled on the daily dosing schedule.
Table 1.
Demographics, baseline characteristics and cancer history (safety population).
Figure 2.
Waterfall plot for best percentage change from baseline in tumor measurement (safety population).
*Patients with MET gene amplification (third individual discontinued therapy before tumor measurement).
Table 2.
Tumor response and disease stabilization (evaluable population).
Table 3.
Treatment-related AEs of all grades reported by ≥10% of patients in either cohort (safety population) and treatment-related AEs of grade 3 and 4.
Figure 3.
Plasma concentrations of foretinib (A), sMET (B), VEGF-A (C) and sVEGFR2 (D) at days 1 and 5, which encompass the first dosing interval of the intermittent 5/9 dosing group.
Box and whisker plots show median ±25% within the box and 100% range of all values within whiskers. Median values for plasma foretinib and each marker shown change significantly over this interval (P<0.0001). Other significant marker changes are discussed in the text.
Figure 4.
Plasma concentrations of sMET (left) and VEGF-A (right) correlate significantly with tumor burden (sum of longest diameters, SLD) at week 8.
Spearman R values were 0.5157 (P = 0.0099) and 0.6216 (P = 0.0012) for sMET and VEGF-A, respectively. The dotted lines indicate 95% confidence intervals.